BICO Group AB ADR (BCCOY)

Overview

BICO Group AB (publ), operating globally with a significant footprint in North America, Europe, Asia, and beyond, positions itself as a pioneering force in the sphere of bioconvergence. Functioning across three distinct yet interrelated segments: Bioprinting, Biosciences, and Bioautomation, the company endeavors to deliver innovative solutions and products that cater to various realms of the medical, pharmaceutical, and cosmetic industries. Originally established under the name Cellink AB (publ), the company transitioned to BICO Group AB (publ) in August 2021, marking a new chapter in its journey since its inception in 2016. With headquartered operations based in Gothenburg, Sweden, BICO has successfully established a robust market presence internationally, supported by a direct sales organization and an extensive network of distributors.

Products and Services

• Bioprinting

This segment underscores BICO’s expertise in advancing 3D cell culture and 3D printing technologies. By delivering a comprehensive range of products, solutions, and services, they empower research and development sectors to proliferate life-like, three-dimensional tissues and organ models. This innovative approach facilitates more realistic drug testing and disease modeling scenarios, propelling the medical and pharmaceutical industries towards more accurate and efficacious outcomes.

• Biosciences

At the core of the Biosciences segment lies a suite of sophisticated instruments designed to streamline the manipulation and analysis of cells and rare samples. These tools, vital for the rapid transfer of liquids and reagents, enable research professionals to perform intricate biological experiments with precision and ease. Furthermore, downstream analysis platforms offered within this segment serve to enhance research capabilities, ultimately accelerating the pace of scientific discoveries and innovation in healthcare.

• Bioautomation

BICO’s Bioautomation segment caters to the needs of life science and diagnostic industries by offering an expansive portfolio of end-to-end products and services. These include precision dispensing, advanced sample preparation, multiplex analysis, assay miniaturization, and the manufacture of diagnostic and medical devices. Such contributions are crucial in optimizing laboratory workflows, increasing throughput, and miniaturizing assays, thereby aiding in the production of diagnostic tools and the development of personalized medicine.